导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -10.65% | 3793/4773 |
| 近一周 | -3.64% | 4853/5465 |
| 近一月 | -3.69% | 2750/5421 |
| 近一季 | -3.05% | 1539/5231 |
| 近半年 | -10.96% | 3720/4920 |
| 近一年 | -17.96% | 3876/4394 |
| 近两年 | 35.45% | 2093/2954 |
| 近三年 | 9.78% | 1763/2253 |
| 成立以来 | -5.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.60% 3654/4961 |
-8.91% 3932/5312 |
- - |
- - |
| 2025 | 25.80% 65/358 |
9.32% 117/340 |
6.87% 166/348 |
20.08% 89/354 |
-10.33% 254/358 |
| 2024 | 5.92% 206/329 |
-6.67% 217/280 |
2.53% 182/310 |
17.32% 103/318 |
-5.65% 245/329 |
| 2023 | -17.05% 181/275 |
-2.79% 168/205 |
-5.25% 176/230 |
-6.57% 186/262 |
-3.60% 221/276 |
| 2022 | -15.41% 70/201 |
-13.63% 105/153 |
6.91% 46/164 |
-21.08% 127/189 |
16.09% 38/202 |
| 2021 | -13.27% 73/150 |
2.68% 114/312 |
7.42% 105/328 |
-11.19% 228/358 |
-11.46% 133/151 |
| 2020 | 13.56% 35/103 |
-13.56% 172/280 |
12.47% 147/295 |
3.92% 112/299 |
12.40% 89/305 |
| 2019 | 28.26% 24/88 |
16.86% 32/258 |
-2.85% 229/267 |
-0.29% 156/253 |
13.31% 22/266 |
| 2018 | - - |
- - |
- - |
- - |
-13.41% 153/241 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华宝香港中小C VS. 长安沪深300非周期A(740101) |